About AminoChain
AminoChain is a company based in New York (United States) founded in 2022 by Caspar Barnes. AminoChain has raised $7.07 million across 1 funding round from investors including Andreessen Horowitz. AminoChain offers products and services including AminoChain Platform and Specimen Center. AminoChain operates in a competitive market with competitors including GenVault Corporation, iSpecimen, Cryoniss, PrecisionMed and ViaCell, among others.
- Headquarter New York, United States
- Founders Caspar Barnes
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.07 M (USD)
in 1 rounds
-
Latest Funding Round
$7.07 M (USD), Series A
Aug 16, 2024
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AminoChain
AminoChain offers a comprehensive portfolio of products and services, including AminoChain Platform and Specimen Center.
Technology connecting stakeholders for biospecimen donation and tracking.
Platform for discovering and acquiring biospecimens for research needs.
Funding Insights of AminoChain
AminoChain has successfully raised a total of $7.07M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.07 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $7.1M
-
First Round
First Round
(16 Aug 2024)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2024 | Amount | Series A - AminoChain | Valuation | a16z |
|
Investors in AminoChain
AminoChain has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Andreessen Horowitz.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AminoChain
Financial Statements - AminoChain
Aminochain Comparisons
Competitors of AminoChain
AminoChain operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenVault Corporation, iSpecimen, Cryoniss, PrecisionMed and ViaCell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biosamples are stabilized, transported, stored, and retrieved by GenVault.
|
|
| domain | founded_year | HQ Location |
Provider of a biorepository of human clinical specimens
|
|
| domain | founded_year | HQ Location |
Provider of biobanking services for life sciences industries
|
|
| domain | founded_year | HQ Location |
Human biological materials for research are supplied via a biorepository.
|
|
| domain | founded_year | HQ Location |
Provider of services for collecting and preserving umbilical cord blood stem cells
|
Latest news on Aminochain
Frequently Asked Questions about AminoChain
AminoChain was founded in 2022 and raised its 1st funding round 2 years after it was founded.
AminoChain is headquartered in New York, United States. It is registered at New York, New York, United States.
Caspar Barnes is the current CEO of AminoChain. They have also founded this company.
AminoChain is a funded company, having raised a total of $7.07M across 1 funding round to date. The company's 1st funding round was a Series A of $7.07M, raised on Aug 16, 2024.
AminoChain was founded in 2022 in New York, United States, within the blockchain and biotechnology sectors. A decentralized platform is operated to tokenize stem cell donations and provide incentives for donors. Connections are facilitated between biobanks, clinical sites, and bio-pharma companies via a bio-sample marketplace. Emphasis is given to secure tokenization processes and donor participation mechanisms.
AminoChain's top competitors include Cryoport, iSpecimen and Clean Cells.
AminoChain offers AminoChain Platform and Specimen Center.
AminoChain has 1 investor. Key investors include Andreessen Horowitz.